24/7
Buzz
Startups
VC
AI
DefenseTech
Opinions
Events
Promising Startups 2026
2026 VC Survey
Boarding Pass
CTalk
BiblioTech
Corporate
Appointments
Tech Gateways
HR - The Next Leap
Ctech Testimonials
Projects
About
Newsletter
Contact us
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Gilead
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
DefenseTech
OPINIONS
EVENTS
Projects
ABOUT
teram of use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
17:49
Iran war forces UAE to rethink one of the world’s biggest AI data center projects
17:08
When AI meets reality, the real revolution begins
17:03
AI is making decades of security advice harder to ignore and easier to apply
11:27
Alice: “The vulnerabilities we identify could affect billions if discovered by the wrong people”
More stories
Buzz
Most popular
Daily
Weekly
1
She sold her startup to Salesforce. Then she had four kids and started another one.
2
Meta loses its $1.5 billion AI recruit less than a year after hiring him
3
Secretive defense startup Covenant emerges from stealth with $250 million at over $1 billion valuation
4
Palo Alto Networks founder Nir Zuk raises $245 million for new cybersecurity startup
5
“We proved there are no sacred cows in technology”: Island founder says the company can be worth tens of billions
More news
Gilead
6 stories about Gilead
Compugen shares soar on massive deal with Gilead, worth up to $848 million
19.12.23
|
Sophie Shulman
The Israeli company utilizes its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing novel cancer immunotherapies
Scientist’s Ex-Wife Joins Legal Melee Over Kite Pharma Windfall
16.01.18
|
Zohar Shahar Levy
Zelig Eshhar, the patent holder for Kite Pharma’s anti-cancer technology, is currently being sued by a former student for infringement of patent rights
CTech’s Daily Israeli Tech News Roundup
10.12.17
|
CTech
Backlash against Trump’s Jerusalem declaration has reached Israeli tech. AmTrust is planning a listing on Tel Aviv Stock Exchange. Teva’s stock is up following news of more layoffs.
Generic Focus made Kite Pharma Founder Leave Teva
13.11.17
|
Dror Reich
Founder of cancer treatment company sold to Gilead Sciences for $12 billion, says Gilead wants “to crack the cancer market"
Meet Kite Pharma's CEO, the Man Bringing Hope to Hodgkin's Lymphoma Patients
30.08.17
|
Dror Reich
With two exits worth hundreds of millions of dollars to his name even before selling Kite Pharma for $12 billion dollars, just where will Arie Belldegrun aim next?
Gilead To Buy Kite Pharma for $11.9 Billion
29.08.17
|
Dror Reich
The drug company is looking to diversify into cell therapy following declining hepatitis c drug sales